At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 495 enrolled
Drug / intervention
BBI608 +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
In Brief
A Phase 2 clinical trial evaluating BBI608, Fluorouracil, and 6 other interventions for Advanced Gastrointestinal Cancer. Completed, enrolled 495 participants across 15 sites in 2 countries.
Detailed Summary
This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Gastrointestinal Cancer
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartJan 2014
Primary CompletionMar 2019
Study CompletionNov 2019
TodayJul 2026
First PostedDec 31, 2013
Enrollment StartJan 1, 2014
Primary CompletionMar 1, 2019
Study CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 12.5 years ago
Interventions
BBI608drug
Fluorouracildrug
Oxaliplatindrug
Leucovorindrug
Irinotecandrug
Bevacizumabdrug
Capecitabinedrug
Regorafenibdrug